Plasma Endothelin-1 and Risk of Death and Hospitalization in Patients Undergoing Maintenance Hemodialysis
- 8 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (6) , 784-793
Abstract
Background and objectives: Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide implicated in the pathogenesis of hypertension, congestive heart failure, and inflammation, all of which are critical pathophysiologic features of CKD. Design, setting, participants, & measurements: To test the hypothesis that plasma endothelin-1 levels are associated with increased risks of mortality and hospitalization in patients with chronic kidney failure, we measured plasma endothelin-1 levels in a prospective cohort of 794 individuals receiving maintenance hemodialysis. The primary outcomes were time to death and time to hospitalization. Results: The median plasma endothelin-1 level was 2.02 (interquartile range, 1.57–2.71) pg/ml. During a median follow-up period of 28 (interquartile range, 21–29) months, 253 individuals (32%) died and 643 individuals (81%) were hospitalized at least once. In multivariable models adjusted for demographic, clinical, and laboratory variables, individuals in the highest quartile of plasma endothelin-1 had a 2.44-fold higher risk of death (hazard ratio, 2.44; 95% confidence interval, 1.61 to 3.70) and a 1.54-fold higher risk of hospitalization (hazard ratio, 1.54; 95% confidence interval, 1.19 to 1.99) compared with individuals in the lowest quartile. The Harrell C-statistic of the fully adjusted model increased from 0.73 to 0.74 after addition of natural log-transformed plasma endothelin-1 (PP=0.002) for hospitalization. Conclusions: Higher plasma endothelin-1 is associated with adverse clinical events in patients receiving hemodialysis independent of previously described risk factors. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_05_15_CJN11130919.mp3Keywords
Funding Information
- National Institutes of Health (U01DK085660, R01DK103784, U01DK104308, UG3DK114915)
- Beijing Nova Program (Z161100004916129)
This publication has 45 references indexed in Scilit:
- Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali dietKidney International, 2010
- Endothelin-1 Increases Glomerular Permeability and Inflammation Independent of Blood Pressure in the RatHypertension, 2010
- Increased ET-1 and Reduced ETBReceptor Expression in Uremic Hypertensive RatsClinical and Experimental Hypertension, 2010
- Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retentionAmerican Journal of Physiology-Renal Physiology, 2006
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Endothelin-1 and big Endothelin-1 in urine and plasma: Investigations in kidney donors, kidney transplant recipients and patients on dialysis.Kidney International, 1999
- Clearance of Circulating Endothelin-1 by ETB Receptors in RatsBiochemical and Biophysical Research Communications, 1994
- Plasma endothelin levels in hypertension and chronic renal failure.Hypertension, 1990
- Tissue distribution and half-life of 125 I-endothelin in the rat: Importance of pulmonary clearanceBiochemical and Biophysical Research Communications, 1990
- Hemodynamic shear stress stimulates endothelin production by cultured endothelial cellsBiochemical and Biophysical Research Communications, 1989